Cabozantinib Impurity 17 | CAS 3697-66-3 - Request Quote
Cabozantinib Impurity 17
| SZ CAT No: | SZ-C112027 |
| CAS No | 3697-66-3 |
| Mol.F. | C7H10O4 |
| Mol.Wt. | 158.2 |
| Inv. Status | Under QC Approval |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Cabozantinib Impurity 17 is chemically 1-(Ethoxycarbonyl)cyclopropane-1-carboxylic acid. Cabozantinib Impurity 17 is supplied with detailed characterization data compliant with regulatory guideline. Cabozantinib Impurity 17 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Cabozantinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 3697-66-3
Purchase 3697-66-3
Order 3697-66-3
Enquire 3697-66-3
price of 3697-66-3
3697-66-3 Supplier
3697-66-3 Manufacturer
3697-66-3 Exporter
buy high quality Cabozantinib Impurity 17
Purchase Cabozantinib Impurity 17
Cabozantinib Impurity 17 suppliers
Cabozantinib Impurity 17 manufacturers
Cabozantinib Impurity 17 price
Order Cabozantinib Impurity 17
Enquire Cabozantinib Impurity 17
Cabozantinib Impurity 17 cost
Cabozantinib Impurity 17 Supplier
Cabozantinib Impurity 17 Distributor
Cabozantinib Impurity 17 for Method Validation
Cabozantinib Reference Standard
Cabozantinib Impurity 17 for ANDA Filing
Cabozantinib Impurity 17 for Forced Degradation Studies
Cabozantinib Impurity 17 Identification Standards
Cabozantinib Impurity 17 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


